CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLCDeposit Agreement • February 27th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
Contract Type FiledFebruary 27th, 2003 Company Industry JurisdictionDEPOSIT AGREEMENT dated as of December 14, 2000 among OXFORD GLYCOSCIENCES PLC, a public limited companyJune 7, 2001, among CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC, incorporated under the laws of England and Wales (herein called the Issuer), THE BANK OF NEW YORK, a New York banking corporation (herein called the Depositary), and all Owners and Beneficial Ownersholders from time to time of American Depositary Receipts issued hereunder.
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC and OXFORD GLYCOSCIENCES PLC and THE BANK OF NEW YORK As Depositary and OWNERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY RECEIPTS Amendment No. 1 dated as of______________, 2003 (to OGS Deposit Agreement...Deposit Agreement • February 27th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
Contract Type FiledFebruary 27th, 2003 Company IndustryThis AMENDMENT NO. 1, dated as of __________, 2003 to the OGS Deposit Agreement (as hereinafter defined), among CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC, incorporated under the laws of England and Wales (herein called the “Company”), OXFORD GLYCOSCIENCES PLC, incorporated under the laws of England and Wales (herein called “OGS”), THE BANK OF NEW YORK, a New York banking corporation (herein called the “Depositary”), and all Owners and holders from time to time of American Depositary Receipts issued hereunder.
Cambridge Antibody Technology Group plc Milstein Building Granta Park Cambridge CB1 6GHDeposit Agreement • February 27th, 2003 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research
Contract Type FiledFebruary 27th, 2003 Company IndustryRe: Deposit Agreement (the "Deposit Agreement") substantially in the form of that filed as an exhibit to the Form F-6 Registration Statement filed with the Securities and Exchange Commission on April 9, 2001, by and among Cambridge Antibody Technology Group plc, The Bank of New York, as Depositary, and al Owners and holders from time to time of American Depositary Receipts issued thereunder